MADRID (Reuters) -A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against ...

The US FDA approves Alcon's dry-eye drug, China bans Brazilian poultry imports due to avian influenza, and various lawsuits ...

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

Change of the Chief Executive Officer (CEO) of Biotest AG28-May-2025 / 17:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

A critical blood shortage is putting pressure on hospital supply chains across South Carolina, as one of the state’s largest blood providers warns that local inventory levels are dangerously low.

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

The positive outlook is based on expectations that Grifols’s operating performance and credit metrics will continue to improve over the next 12-18 months. Specifically, its gross leverage is ...

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A Leeds-based creator of simulation software to train medical staff on laboratory equipment has secured £1m investment.

The US Food and Drug Administration (FDA) has cleared Grifols' investigational new drug (IND) application to initiate a Phase ...